Table 3.
Antimicrobial therapy management related to Stenotrophomonas maltophilia hospital-acquired pneumonia
| Variables | Total N = 282 |
|---|---|
| Number of antimicrobial therapy lines administered within 30 days before diagnosis (median [IQR]) | 3 [2–4] |
| Number of days with initial ineffective antimicrobial therapy on S. maltophilia (median [IQR]) | 2 [2–3.5] |
| Most commonly prescribed antimicrobial agents before S. maltophilia HAP onset (n, (%)) | |
| Amoxicillin | 20 (7.1) |
| Amoxicillin–clavulanate | 61 (21.6) |
| Third-generation cephalosporin | 93 (33) |
| Cefepime | 25 (8.9) |
| Ceftazidime | 17 (6) |
| Ticarcillin | 4 (1.4) |
| Ticarcillin–clavulanate | 10 (3.5) |
| Piperacillin | 15 (5.3) |
| Piperacillin–tazobactam | 97 (34.4) |
| Carbapenem | 63 (22.3) |
| Aminoglycoside | 70 (24.8) |
| Fluoroquinolone | 40 (14.2) |
| Trimethoprim–sulfamethoxazole | 9 (3.2) |
| Glycopeptide | 59 (20.9) |
| Metronidazole | 32 (11.3) |
| Linezolid | 31 (11) |
| Others | 71 (25.2) |
| Empirical antimicrobial therapy (n, (%)) | 166 (58.8) |
| Number of antimicrobial agents for empirical antimicrobial therapy (median, [IQR]) | 1 [0–2] |
| Efficient empirical therapy on S. maltophilia (n, (%)) | 50 (30.1) |
| Combination antimicrobial therapy (2 or more) targeting S. maltophilia (n, (%)) | 167 (59.4) |
| Duration of antimicrobial therapy targeting S. maltophilia, days (median, [IQR]) | 11 [7–15] |
| Duration of combined (2 or more) antimicrobial therapy targeting S. maltophilia, days (median, [IQR]) | 7 [5–12] |
S. maltophilia is intrinsically resistant to amoxicillin, amoxicillin/clavulanate, ticarcillin, piperacillin/tazobactam, carbapenems, and aminoglycosides (EUCAST expert rules version 3.1—26 Sept 2016). Data are presented as median, interquartile range ([IQR]), or number (percentage) (n, (%)) as appropriate
HAP hospital-acquired pneumonia